The approval of the break point cluster (BCR)-Abelson (ABL) tyrosine-kinase inhibitor (TKI) imatinib for chronic myelogenous leukemia (CML) in 2001 heralded the era of targeted therapy [6–8]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.